Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is a biopharmaceutical company focused on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH). The company is known for its innovative approach to addressing liver-related diseases. As of November 21, 2025, H.C. Wainwright set a price target of $620 for MDGL, suggesting a potential increase of approximately 10.99% from its then-current price of $558.61.
Recently, Madrigal announced the granting of equity awards to three new non-executive employees. These awards are part of the company's 2025 Inducement Plan, approved by the independent Compensation Committee. The awards include 2,125 time-based restricted stock units, which will vest over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract and retain talent.
MDGL is currently trading at $563.96, reflecting a 4.03% rise with a price increase of $21.84. The stock has shown volatility, with today's trading range between $535 and $564.90. Over the past year, MDGL has seen a high of $577.90 and a low of $265, indicating significant price fluctuations.
The company's market capitalization is approximately $12.51 billion, highlighting its substantial presence in the biopharmaceutical sector. With a trading volume of 241,697 shares, MDGL remains an actively traded stock on the NASDAQ. The recent price target set by H.C. Wainwright suggests confidence in the company's future growth potential.
